Lisdexamfetamine to improve excessive daytime sleepiness and weight management in narcolepsy: a case series

Aguilar, Ana Carolina; Frange, Cristina; Filho, Lúcio Huebra Pimentel; Reis, Maria Júlia Figueiró; Tufik, Sérgio; Coelho, Fernando Morgadinho Santos

doi:10.1590/1516-4446-2019-0544

Cited by 7 publications

(2 citation statements)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, further research is needed to establish the efficacy and safety of this drug. 57 We highlight the use of atypical stimulants known as modafinil and armodafinil, which are included in many guidelines around the world for narcolepsy treatment. 54 Modafinil improves wakefulness at 100 to 400 mg doses in adults but does not affect controlling cataplexy.…”

Section: Treatmentmentioning

confidence: 99%

Narcolepsy: an interface among neurology, immunology, sleep, and genetics

Coelho

2024

Arq Neuropsiquiatr

Self Cite

View full text Add to dashboard Cite

Narcolepsy is a primary disorder of the central nervous system resulting from genetic, environmental, and immunological interactions defined as excessive daytime sleepiness plus cataplexy, hallucinations, sleep paralysis, and sleep fragmentation. The pathophysiology is not entirely known, but the interaction among genetic predisposition, environmental exposition, and immune component with consequent hypocretin-1 deficiency is the model to explain narcolepsy type I. The mechanism of narcolepsy type II is less understood. There is a delay of over ten years for the diagnosis of narcolepsy around the world. Patients with narcolepsy have many comorbidities with a negative impact on quality of life. The treatment of narcolepsy must contain an educational approach for the family, coworkers, and patients. Scheduled naps and sleep hygiene are essential to minimize the dose of medications. Much progress has been seen in the pharmacological treatment of narcolepsy with new stimulants, different presentations of oxybate, and recent studies with orexin agonists. Narcolepsy is a rare disease that needs to be more understood and highlighted to avoid delayed diagnosis and severe disabilities in patients.

show abstract

Section: Treatmentmentioning

confidence: 99%

Narcolepsy: an interface among neurology, immunology, sleep, and genetics

Coelho

2024

Arq Neuropsiquiatr

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, evidence from meta-analyses is frequently biased, and the credibility of the claimed associations between putative risk or protective factors for personality disorders remains unknown. To fill this gap in the literature, we conducted an umbrella review focused on environmental risk and protective factors for personality disorders, to identify and measure possible methodological limitations and sources of bias in the published and unpublished evidence, which might have underestimated or inflated claimed associations, as previously shown in several previous umbrella reviews on risk factors for mental disorders or obesity ( 13 – 17 ). Therefore, the aim of this umbrella review was to grade the evidence from meta-analyses of cohort and case–control studies on protective and risk factors for personality disorders accounting for several sources of bias and applying established quantitative criteria.…”

Section: Introductionmentioning

confidence: 99%

Risk and Protective Factors for Personality Disorders: An Umbrella Review of Published Meta-Analyses of Case–Control and Cohort Studies

et al. 2021

View full text Add to dashboard Cite

The putative risk/protective factors for several personality disorders remain unclear. The vast majority of published studies has assessed personality characteristics/traits rather than disorders. Thus, the current umbrella review of meta-analyses (MAs) aims to systematically assess risk or protective factors associated with personality disorders. We searched PubMed–MEDLINE/PsycInfo databases, up to August 31, 2020. Quality of MAs was assessed with AMSTAR-2, while the credibility of evidence for each association was assessed through standard quantitative criteria. Out of 571 initial references, five meta-analyses met inclusion criteria, encompassing 56 associations of 26 potential environmental factors for antisocial, dependent, borderline personality disorder, with a median of five studies per association, and median 214 cases per association. Overall, 35 (62.5%) of the associations were nominally significant. Six associations met class II (i.e., highly suggestive) evidence for borderline personality disorder, with large effect sizes involving childhood emotional abuse (OR = 28.15, 95% CI 14.76–53.68), childhood emotional neglect (OR = 22.86, 95% CI 11.55–45.22), childhood any adversities (OR = 14.32, 95% CI 10.80–18.98), childhood physical abuse (OR = 9.30, 95% CI 6.57–13.17), childhood sexual abuse (OR = 7.95, 95% CI 6.21–10.17), and childhood physical neglect (OR = 5.73, 95% CI 3.21–10.21), plus 16 further associations supported by class IV evidence. No risk factor for antisocial or dependent personality disorder was supported by class I, II, and III, but six and seven met class IV evidence, respectively. Quality of included meta-analyses was rated as moderate in two, critically low in three. The large effect sizes found for a broad range of childhood adversities suggest that prevention of personality disorders should target childhood-related risk factors. However, larger cohort studies assessing multidimensional risk factors are needed in the field.

show abstract

Narcolepsy: An Overview

Coelho¹,

Gomes²

2021

Sleep Medicine and Physical Therapy

View full text Add to dashboard Cite

Lisdexamfetamine to improve excessive daytime sleepiness and weight management in narcolepsy: a case series

Cited by 7 publications

References 22 publications

Narcolepsy: an interface among neurology, immunology, sleep, and genetics

Narcolepsy: an interface among neurology, immunology, sleep, and genetics

Risk and Protective Factors for Personality Disorders: An Umbrella Review of Published Meta-Analyses of Case–Control and Cohort Studies

Narcolepsy: An Overview

Contact Info

Product

Resources

About